|
|
琥珀酸脱氢酶缺陷型肾细胞癌研究进展 |
陈怡1, 李明2 综述, 张涛2 审校 |
100027,武警北京总队医院:1.检验与病理科,2.内三科 |
|
[1] |
Vanharanta S, Buchta M, McWhinneyS R, et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma[J]. Am J Hum Genet, 2004, 74(1): 153-159.
|
[2] |
Moch H, Cubilla A I, Humphrey P A,et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, testicular tumours[J].Eur Urol, 2016, 70(1): 93-105.
|
[3] |
Burnichon N,Brière J J,Libé R,et al.SDHA is a tumor suppressor gene causing paraganglioma[J].Hum Mol Genet,2010,19(15):3011-3020.
|
[4] |
Zhao T,Mu X,You Q.Succinate: an initiator in tumorigenesis and progression[J].Oncotarget,2017,8(32): 53819-53828.
|
[5] |
Rizza S,Montagna C,Cardaci S,et al.S-nitrosylation of the mitochondrial chaperone TRAP1 sensitizes hepatocellular carcinoma cells to inhibitors of succinate dehydrogenase[J].Cancer Res,2016,76(14):4170-4182.
|
[6] |
Ishii T,Miyazawa M,Onouchi H,et al.Model animals for the study of oxidative stress from complex II[J].Biochim Biophys Acta,2013,1827(5):588-597.
|
[7] |
Mu X,Zhao T,Xu C,et al.Oncometabolite succinate promotes angiogenesis by upregulating VEGF expression through GPR91-mediated STAT3 and ERK activation[J].Oncotarget,2017,8(8):13174-13185.
|
[8] |
Astuti D, Latif F, Dallol A, et al. Gene mutation in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma[J]. Am J Hum Genet, 2001,69(1):49-54.
|
[9] |
Menendze J A, Alarcon T, Joven J. Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites[J]. Cell Cycle,2014, 13(5):699-709.
|
[10] |
Williamson S R, Eble J N, Amin M B, et al. Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma[J]. Mod Pathol, 2015,28(1):80-94.
|
[11] |
Gill A J, Ondrej H, Thomas P, et al. Succinate dehydrogenase(SDH)-deficient renal carcinoma : a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients[J]. Am J Surg Pathol, 2014,38(12):1588-1602.
|
[12] |
武 静,成元华,张亚娟,等.琥珀酸脱氢酶缺陷型肾细胞癌的临床病理特征[J].实用医学杂志,2019,35(14):2304-2307.
|
[13] |
刘浩然,叶章群.肾癌基础研究新进展[J].现代泌尿生殖肿瘤杂志,2017, 9(5):257-261.
|
[14] |
Kuroda N, Yorita K, Nagasaki M, et al. Review of succinate dehydrogenase-deficient renal cell carcinoma with focus on clinical and pathobiological aspects[J]. Pol J Pathol,2016, 67(1):3-7.
|
[15] |
田 佳,莫文法,陆文恺,等.琥珀酸脱氢酶B缺陷相关的肾细胞癌转移至颈部一例[J].中华病理学杂志, 2018,47(8): 641-642.
|
[16] |
Sun A,LiuZ S, Wang T,et al. Succinate dehydrogenase-deficient renal cell carcinoma: a case report and review of the literature[J].Asian J Surg,2021,44(4):692-693.
|
[17] |
Ozluk Y, Taheri D, Matoso A, et al. Renal carcinoma associated with a noval succinate dehydrogenase a mutation: a case report and review of literature of a rare subtype of renal carcinoma[J]. Hum Pathol,2015, 46(12):1951-1955.
|
[18] |
Yakirevich E, Ali S M, Mega A, et al. A novel SDHA-deficient renal cell carcinoma revealed by comprehensive genomic profiling[J]. Am J Surg Pathol, 2015, 39(6):858-863.
|
[19] |
Ricketts C J,Shuch B,Vocke C D,et al.Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer[J].J Urol,2012,188(6):2063-2071.
|
[20] |
肖 芹,陈 静,刘 丹,等.琥珀酸脱氢酶缺陷型肾细胞癌的临床病理分析[J].中华病理学杂志,2019,48(10):796-798.
|
[21] |
赵 媛,陈 红,金木兰. 琥珀酸脱氢酶缺陷型肾癌1例并文献复习[J]. 临床与实验病理学杂志,2019, 35(12):1472-1474.
|
[22] |
Aghamir S,Heshmat R,Ebrahimi M,et al.The impact of succinate dehydrogenase gene (SDH) mutations in renal cell carcinoma (RCC): a systematic review[J].Onco Targets Ther,2019, 9(12):7929-7940.
|
[23] |
Paik J Y, Toon C W, Benn D E, et al. Renal carcinoma associated with B mutation: a new and unique subtype of renal carcinoma[J]. J Clin Oncol, 2014,32(6):e10-13.
|
[24] |
McEvoy C R, Koe L, Choong D Y, et al. SDH-deficient renal cell carcinoma associated with biallelic mutation in succinate dehydrogenase A: comprehensive genetic profiling and its relation to therapy response[J]. NPJ Precis Oncol, 2018,2(1):1-5.
|
[1] |
郭启, 李贤慧, 王志强. 肾细胞癌骨转移的研究进展[J]. 武警医学, 2021, 32(7): 632-637. |
[2] |
孟玫, 焦健, 刘洁, 张鹏. 双侧肾上腺髓样脂肪瘤合并21α-羟化酶缺陷症1例[J]. 武警医学, 2021, 32(5): 429-430. |
[3] |
寇天雷, 何滔, 郑淑芳, 何轩. 嗜酸性实性及囊性肾细胞癌1例[J]. 武警医学, 2020, 31(4): 345-347. |
[4] |
王晓红,刘然. 老年人胃肠道间质瘤的c-kit和PDGFRa基因突变检测[J]. 武警医学, 2019, 30(3): 237-239. |
[5] |
张亚妹, 万乃君, 孙慧慧. 软骨发育不全1例临床特点及其基因突变分析[J]. 武警医学, 2018, 29(2): 159-162. |
[6] |
吴学宾,吴玮玮. 慢性中性粒细胞白血病的研究进展[J]. 武警医学, 2016, 27(10): 973-978. |
[7] |
胡兴胜. 内皮生长因子受体突变非小细胞肺癌精准个体化治疗[J]. 武警医学, 2015, 26(8): 757-760. |
[8] |
朱柏贵,张苏江,李建勇,高鸿敏. FLT3基因突变对急性髓系白血病的影响[J]. , 2014, 25(5): 478-480. |
[9] |
范天勇,万 繁. 腹腔镜肾细胞癌手术相关问题与系统评价[J]. 武警医学, 2013, 24(2): 93-96. |
[10] |
康静波,聂青,张丽萍,张军,李启亮,朱奇. 立体定向放射治疗配合靶向药物索拉非尼治疗复发[J]. 武警医学, 2012, 23(6): 465-467. |
[11] |
管德辉;王晓民;苏 宇;王科亮;徐万海 . 肾细胞癌患者手术前后外周血T淋巴细胞亚群的变化及其临床意义[J]. , 2012, 23(3): 7-7. |
[12] |
朱柏贵;张苏江;李建勇. NPM1基因突变在急性髓系白血病中的作用[J]. , 2010, 21(07): 575-577,. |
[13] |
杨丽云;丁琪;赵怡雯;任素梅;达万明;朱平;张振文. 木村病与穿孔素基因突变的研究[J]. , 2010, 21(01): 51-54. |
[14] |
穆瑞国;任改瑛. 对严重缺陷新生儿放弃治疗的伦理学思考[J]. , 2009, 20(09): 858-859. |
[15] |
陈然峰;陈国军;陈启荣;黄志勇;金晓东;杨勇. 乙型肝炎病毒基因突变后的修复及其肝细胞损伤变化[J]. , 2008, 19(06): 519-521. |
|
|
|
|